PCSK9-IN-10
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia[1].
Product Specifications
CAS Number
368434-98-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/pcsk9-in-10.html
Purity
98.89
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(N1C)N(C)C2=C(N(CC3=CC=CC(OC)=C3)C(NCCOC)=N2)C1=O
Molecular Formula
C18H23N5O4
Molecular Weight
373.41
Precautions
H302, H315, H319
References & Citations
[1]Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH032899-01 10 µg
Recombinant Human PLA2G1B/PLA2 Protein (His Tag)
Sign In for Pricing
View Details PKSH032899-02 50 µg
Recombinant Human PLA2G1B/PLA2 Protein (His Tag)
Sign In for Pricing
View Details 
BNC880693-500 1x 500 µL
CD56 / NCAM (123C3.D5 + 123A8), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details